Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
about
Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomasNuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivoExpression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro.Gene expression analysis of dendritic/Langerhans cells and Langerhans cell histiocytosis.Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.Epstein-Barr virus-associated Hodgkin's lymphoma.An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.Human Immunodeficiency Virus Infection and Hodgkin's Lymphoma in South Africa: An Emerging ProblemCost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers.Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell typesPlasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells.Aberrant Circulating Th17 Cells in Patients with B-Cell Non-Hodgkin's LymphomaThe role of interleukin-3 in classical Hodgkin's disease.CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration.MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines.Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.The inflammatory chemokine CCL5 and cancer progressionAnti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.Prognostic biomarkers in malignant lymphomas.Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.Hodgkin disease and the role of the immune system.Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.The neoplastically transformed (CD30hi) Marek's disease lymphoma cell phenotype most closely resembles T-regulatory cells.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Consecutive stimulation of HBsAg promotes the viability of the human B lymphoblastoid cell line IM-9 through regulating the SIRT1-NF-κB pathway.Mechanisms underlying the association between obesity and Hodgkin lymphoma.Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma.Modeling the proteome of a Marek's disease transformed cell line: a natural animal model for CD30 overexpressing lymphomas.Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.
P2860
Q24675877-A4CDFBFF-0877-4AF6-87D9-74294997C7B0Q31090571-F2984A18-A497-4D23-8584-1A34B42267F3Q33210744-B70EC99C-8499-453D-9380-F5587B58D56FQ33244330-F2E2C3DB-5B33-49A9-8B88-7FD47B5C0785Q34022527-6B80C4F1-B3FD-4FB7-A1AC-5D99AB856309Q34313818-6649F892-7052-4A58-97FC-8A9C096141A3Q34427113-0AC91460-26F4-46F1-8EB6-2E747B11D924Q34571564-39BE1E72-CC99-4E63-90B7-9CC642645395Q34620222-36D1B7F4-22D3-465E-AB1E-061BC93DE3CAQ34708248-38C626CD-FD6D-4CBA-9476-6418567ACBEFQ35017864-3D435EA4-8284-4E49-9407-7B5CB3677F68Q35223868-3A7F87E7-1E26-4B17-AC57-6DDA476FF19DQ35791596-335C024A-CBF0-4AEA-A3EC-498F3DE87BFDQ35794450-02D39B7C-4124-446F-BF50-AD8A13109E02Q35820996-AFF5D7AD-A5A1-431A-93CC-5155B4325B10Q35905076-BFC13A93-C67E-46CD-8DD0-C81A88B0C5DAQ35994955-1D28B423-114B-4A59-B151-8B46DE886A26Q36288217-CE7564EC-475C-4E08-9C48-1C8F4871ED5AQ36303951-C62FF1F8-874F-4F41-996E-45A7DDBDDA68Q36505005-71338B20-15D4-419D-A28C-85440E0F9555Q36734930-39F7A893-B7FD-4E0D-B1DA-B3E52EFD8815Q37057742-8B081C99-1133-4631-8F73-A9BE68FE4BB3Q37262460-026CBD59-442A-460A-AA30-C7FC70D8A338Q37271829-1123D090-4140-4593-B8AE-D553DA9B2F59Q37541911-F0B6493C-70A4-409F-8721-CCE9D9F6B8D2Q37729133-5EFE67AB-49FC-4A39-AFBE-8870C7FD9996Q37763027-5E95C60F-6BFA-4D86-A28A-04DDB6FDC5CFQ37775634-54D26F61-A732-40B3-88A1-24205B37513BQ37832198-0BA53F23-7D1A-4B97-888E-5B74F4ACBE61Q37850445-4E60D5A3-76A5-405F-9964-A05B7B6EE623Q38430117-6EE4D909-FF2A-44B0-B101-389A063BA888Q38514428-1C1FEF5C-59BA-46C0-A68C-7C531FC82562Q38557033-04EBE3F2-FA34-4713-8D99-E86D78E8C6F6Q38697681-2BF45FC4-2CE5-4D16-9AD7-B1381B56CC42Q38910560-EC6D5BFC-C86A-4CBE-82F8-5EDBAB965EECQ39950363-18B9FC4A-A355-46DE-BA39-E161B8C280C7Q40143912-18E66FBD-2106-4022-AADE-318B240FC505Q40564995-BDB33AAB-E922-4A99-A42C-ED00F73B9621Q40625623-718AF596-CC46-46E7-A69F-FC4AD00C0103Q41996270-898C2515-9959-4813-9B10-75C10D5942E2
P2860
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@ast
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@en
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@nl
type
label
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@ast
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@en
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@nl
prefLabel
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@ast
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@en
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@nl
P2093
P356
P1433
P1476
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.
@en
P2093
P356
10.1093/ANNONC/13.S1.52
P478
13 Suppl 1
P577
2002-01-01T00:00:00Z